Profile Response Detail

Molecular Profile ALK rearrange MET amp
Therapy Crizotinib
Indication/Tumor Type lung adenocarcinoma
Response Type sensitive
Create By cstatz
Update By cstatz


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ALK rearrange MET amp lung adenocarcinoma sensitive Crizotinib Case Reports/Case Series Actionable In a clinical case study, a lung adenocarcinoma patient harboring an ALK rearrangement who developed resistance to Alecensa (alectinib) likely due to acquisition of MET amplification, responded well to treatment with Xalkori (crizotinib), demonstrating a radiological response after 12 days (PMID: 24128725, PMID: 24518097). 24128725 24518097
PubMed Id Reference Title Details
(24128725) Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation. Full reference...
(24518097) Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor? Full reference...